Neogen Q1: consolidated PAT jumps 67% YoY to ₹17.1 Cr, revenue up 34%, margins expand
PAT +66.76% YoY · revenue +34.04% · margins expanding
₹250.29 Cr
+34.04% YoY
₹17.11 Cr
+66.76% YoY
6.73%
+1.3pp YoY
₹6.29
Neogen Chemicals opened FY27 with a strong operating print. Consolidated revenue rose 34% YoY to ₹250.29 Cr (up a marginal 1.5% QoQ off a seasonally strong Q4) and net profit climbed 66.8% YoY to ₹17.11 Cr. The profit outpaced revenue because margins widened on the operating line, not on one-offs: operating margin expanded to 19.35% from 16.87% a year ago, and net margin to 6.83% from 5.46%. There were no exceptional items this quarter, so the growth is clean — the prior-year Dahej fire exceptional sat in FY25, outside the Q1 FY26 base.
Q1 FY-2027 vs prior quarters
The standalone base business grew more evenly — revenue +36.7% and PAT +36.6% YoY to ₹19.44 Cr — and the gap between standalone and consolidated PAT tells the real story: consolidated profit (₹17.11 Cr) still sits below standalone because the subsidiaries, chiefly the battery-chemicals arm Neogen Ionics, remain a net drag of about ₹2.4 Cr for the quarter. That drag is narrowing versus a year ago, which is why consolidated PAT growth (+67%) runs well ahead of standalone (+37%). Against management's FY27 guidance of ₹875–950 Cr standalone revenue (excluding battery chemicals), the Q1 standalone run-rate of ₹252 Cr is tracking at or above the top of the range, consistent with the confident tone struck on the Q4 concall; the >₹300 Cr battery-chemicals contribution management guided for is still H2-weighted as Dahej/Pakhajan ramp.
The stock went into the print at ₹2,062.8, up 6.1% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 2 consecutive quarters; revenue is at a 6-quarter high.
Neogen Chemicals provided strong forward-looking guidance. For FY27, standalone revenue is projected to be between INR 875 to INR 950 crore, excluding any battery chemicals revenue. The battery chemicals business (Neogen Ionics) is expected to generate over INR 300 crore in FY27, with the majority of sales anticipated
— This quarter: met
The quarter was not without pressure points. Crisil downgraded Neogen on July 17 — short-term to A2 (from A1) and long-term to A-/Negative (from A/Negative) — pushing the coupon on its ₹200 Cr NCDs from 10.50% to 11.00%, and consolidated finance costs already rose to ₹20.81 Cr from ₹12.67 Cr YoY on higher debt. Alongside the results the board approved an in-principle ₹600 Cr fundraise (including a possible QIP) and ₹500 Cr of borrowing headroom for step-down subsidiary Neogen Morita New Materials — signalling the capex-heavy battery push continues. On the fire claim, the group has received ₹140 Cr on-account (₹15 Cr more after quarter-end), with ₹200.85 Cr of claim still receivable; it is treated as fully recoverable and carries no P&L impact this quarter. No formal street consensus is published for this quarter.
W1
Standalone run-rate vs FY27 guidance of ₹875–950 Cr (ex-battery): Q1 ₹252 Cr annualizes above the top — watch sustainability into H2.
W2
Neogen Ionics battery chemicals: management guided >₹300 Cr in FY27, majority H2 as Dahej/Pakhajan ramp — track subsidiary swing from ~₹2.4 Cr loss toward profit.
W3
Debt cost trajectory post-Crisil downgrade (NCD coupon now 11%) and execution of the ₹600 Cr fundraise; finance costs already ₹20.81 Cr/qtr.
Clean digital PDF, both statements present. No exceptional items this quarter (prior-year fire exceptional sat in FY25, not in the Q1 FY26 comparison base, so YoY is unadjusted). Consolidated PBT includes ₹0.20 Cr JV share; consolidated tax = 6.03 current + 0.14 deferred = 6.17. Consolidated PAT (17.11) < standalone (19.44) — subsidiaries a net drag of ~₹2.4 Cr (battery-chem Neogen Ionics ramp). Crisil rating downgrade (Jul 17) and ₹600 Cr fundraise approval are same-day/near-term events, not exceptional items.
Informational and educational content only. Not investment advice.